Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
332 |
Employees |
10,500 |
Revenues (TTM) (Millions $) |
16,096 |
Net Income (TTM) (Millions $) |
-2,479 |
Cash Flow (TTM) (Millions $) |
211 |
Capital Exp. (TTM) (Millions $) |
479 |
Allergan Plc
Allergan, Inc. is a technology-driven, global health care company that develops
and commercializes specialty pharmaceutical products for the ophthalmic, neurological,
dermatological and other specialty markets. We are a pioneer in specialty pharmaceutical
research, targeting products and technologies related to specific disease areas
such as glaucoma, retinal disease, dry eye, psoriasis, acne and movement disorders.
Additionally, we develop and market aesthetic-related pharmaceuticals and over-the-counter
products. Within these areas, we are an innovative leader in therapeutic and other
prescription products, and to a limited degree, over-the-counter products that
are sold in more than 100 countries around the world. We are also focusing research
and development efforts on new therapeutic areas, including gastroenterology,
neuropathic pain and various types of cancer.
We were originally incorporated in California in 1948 and became known as Allergan
Corporation in 1950. In 1977, we reincorporated in Delaware. In 1980, we were
acquired by SmithKline Beecham plc (then known as SmithKline Corporation). From
1980 through 1989, we operated as a wholly-owned subsidiary of SmithKline and
in 1989 we again became a stand-alone public company through a spin-off distribution
by SmithKline.
On June 29, 2002, we completed the spin-off of our optical medical device business
to our stockholders. The optical medical device business consisted of two businesses:
our ophthalmic surgical products business, which developed, manufactured and
marketed products that included artificial lenses for the eye, called intraocular
lenses, and equipment for cataract and refractive eye surgery; and our contact
lens care products business, which developed, manufactured and marketed a broad
range of products for use with every available type of contact lens. The spin-off
was effected by contributing our optical medical device business to a newly
formed subsidiary, Advanced Medical Optics, Inc., and issuing a dividend of
Advanced Medical Optics’ common stock to our stockholders. The Internal Revenue
Service ruled that the transaction qualified as tax-free for Allergan and our
stockholders for U.S. federal income tax purposes, with the exception of cash
received for fractional shares. The common stock of Advanced Medical Optics
began trading publicly on the New York Stock Exchange on July 1, 2002 under
the symbol “AVO.” Following the spin-off, we continue to own and operate our
specialty pharmaceutical business and Advanced Medical Optics owns and operates
what was formerly our optical medical device business. We have no ownership
interest in Advanced Medical Optics. Our consolidated financial statements and
related notes reflect the financial position, results of operations and cash
flows of the optical medical device business as a discontinued operation.
Competition
We face significant competition in all of our markets worldwide. Numerous companies
are engaged in the development, manufacture and marketing of health care products
competitive with those that we manufacture. Our major eye care competitors include
Alcon Laboratories, Inc., Bausch & Lomb, Pfizer, Novartis Ophthalmics and
Merck & Co., Inc. These competitors have equivalent or, in most cases, greater
resources than us. Our skin care business competes against a number of companies,
including among others, Dermik, a division of Aventis, Galderma, a joint venture
between Nestle and L’Oreal, Bristol-Myers Squibb, Schering-Plough Corporation,
Johnson & Johnson and Hoffman-La Roche Inc., all of which have greater resources
than us. In the market for neuromodulators, we have three competitors, including
Beaufour Ipsen Ltd., which sells products in Europe, Latin America, Asia, Australia
and New Zealand, Elan Pharmaceuticals, which sells products in the United States
and Europe, and a Chinese entity which sells products in limited countries in
Asia and Latin America. In marketing our products to health care professionals,
pharmacy benefits management companies, health care maintenance organizations,
and various other national and regional health care providers and managed care
entities, we compete primarily on the basis of product technology and price.
We believe that we compete favorably in our product markets.
Company Address: Clonshaugh Business and Technology Park Dublin 0
Company Phone Number: 261-7000 Stock Exchange / Ticker: NYSE AGN
|